This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSML
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSML
SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SGRY vs. DOCS: Which Stock Is the Better Value Option?
Down -6.99% in 4 Weeks, Here's Why You Should You Buy the Dip in Doximity (DOCS)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Doximity (DOCS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
All You Need to Know About Doximity (DOCS) Rating Upgrade to Buy
by Zacks Equity Research
Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ICLR vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICLR vs. DOCS: Which Stock Is the Better Value Option?
Compared to Estimates, Doximity (DOCS) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Doximity (DOCS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Doximity (DOCS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 20.83% and 6.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Doximity (DOCS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Doximity (DOCS) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Doximity (DOCS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Doximity (DOCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Industry Outlook Highlights Medpace, Doximity and Biodesix
by Zacks Equity Research
Medpace, Doximity and Biodesix have been highlighted in this Industry Outlook article.
Earnings Estimates Moving Higher for Doximity (DOCS): Time to Buy?
by Zacks Equity Research
Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Medical Services Stocks to Buy as Industry Trends Improve
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, DOCS and BDSX are set to gain the most. However, staffing shortages may disrupt the growth trend.
ICLR or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICLR vs. DOCS: Which Stock Is the Better Value Option?
Doximity (DOCS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Doximity (DOCS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Doximity (DOCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Doximity (DOCS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Doximity (DOCS) stock based on the movements in the options market lately.
MD or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. DOCS: Which Stock Is the Better Value Option?
Implied Volatility Surging for Doximity (DOCS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Doximity (DOCS) stock based on the movements in the options market lately.
Here's What Key Metrics Tell Us About Doximity (DOCS) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Doximity (DOCS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Doximity (DOCS) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 26.67% and 1.40%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
DocGo Inc. (DCGO) delivered earnings and revenue surprises of -166.67% and 4.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of -3.45% and 3.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 9.09% and 0.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ELV or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. DOCS: Which Stock Is the Better Value Option?